Injectafer® (ferric carboxymaltose) is now the first and only intravenous (i.v.) iron replacement therapy in the U.S. indicated for improvement in exercise capacity in adult patients with symptomatic heart failure who have iron deficiency ST. GALLEN, Switzerland, June 5, 2023 /PRNewswire/ -- CSL Vifor today announced that the U.S. Food and Drug Administration (FDA) has granted its partner American Regent, Inc., a Daiichi Sankyo Group company, approval for Injectafer ® for the treatment of iron d

Cardinal Health's Outcomes™ business will combine with Transaction Data Systems to offer improved patient engagement and clinical pharmacy solutions, expanding connections between payers and pharma to its nationwide pharmacy network DUBLIN, Ohio, June 5, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced it has signed a definitive agreement to contribute its Outcomes™ business to Transaction Data Systems (TDS), a portfolio company of BlackRock Long Term Private Capital and GTCR, in

Injectafer® (ferric carboxymaltose) is now the first and only intravenous (i.v.) iron replacement therapy in the U.S. indicated for improvement in exercise capacity in adult patients with symptomatic heart failure who have iron deficiency ST. GALLEN, Switzerland, June 5, 2023 /PRNewswire/ -- CSL Vifor today announced that the U.S. Food and Drug Administration (FDA) has granted its partner American Regent, Inc., a Daiichi Sankyo Group company, approval for Injectafer ® for the treatment of iron d

SOMERSET, N.J., June 5, 2023 /PRNewswire/ -- Doctors at ProCure Proton Therapy Center are raising awareness of a new study that predicts a surge in cancer cases due to pandemic-induced screening delays. The study, published last month in the Journal of the American College of Surgeons (JACS), used a predictive statistical model to quantify missed diagnoses of lung, breast, and colorectal cancers by comparing observed cancer rates in 2020 with pre-pandemic cancer rates (2010-2019). Researchers f

Empire Whole Health Heroes Awards to recognize individuals and organizations committed to innovation and leadership NEW YORK, June 5, 2023 /PRNewswire/ -- As part of its mission to materially and measurably improve the health of all New Yorkers, Empire BlueCross BlueShield, in partnership with the custom division of Crain's New York Business, is pleased to launch the 2023 Empire Whole Health Heroes Awards program. Empire and Crain's are continuing this program to recognize individuals and organi

SAN DIEGO, June 5, 2023 /PRNewswire/ -- Cellibre Inc., a leading manufacturing technology company, today announced that the team will participate in the Jefferies 2023 Global Healthcare Conference taking place June 7-9, 2023 in New York, NY. About Cellibre Cellibre is a manufacturing technology company that employs an organism-agnostic approach to turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Cellibre's world-class scientific t

Updated data from Phase 3 AGILE study show additional extension in median overall survival to 29.3 months with TIBSOVO® (ivosidenib tablets) in combination with azacitidine and confirm continued benefit of TIBSOVO as first-line treatment of newly-diagnosed acute myeloid leukemia (AML) Analysis of Phase 1 expansion study identifies clinical and molecular characteristics of AML patients with an exceptional response to TIBSOVO BOSTON, June 5, 2023 /PRNewswire/ -- Servier, a leader in oncology comm

TEMPLE, Texas, June 5, 2023 /PRNewswire/ -- Good Vibes Homeopathic Healing is excited to announce the launch of the world's first-ever plant identifier app that goes beyond simply identifying plants to exploring their potential medicinal benefits. Developed by renowned expert in homeopathic healing, Tony C. Nora, the Herb Nerd Pro app is set to revolutionize the world of natural remedies and plant-based healthcare. Continue Reading Herb Nerd Pro is not just a plant identifier app, it's a compreh

SEOUL, South Korea, June 5, 2023 /PRNewswire/ -- On June 2nd, Daewoong Pharmaceutical (CEO Jeon Sengho, Lee Changjae) today announced that it and Neurogastrx have agreed to terminate the June 2021 license agreement, which granted Neurogastrx exclusive right to develop and commercialize Fexuprazan with respect to the U.S. and Canada market. Neurogastrx has re-evaluated its development pipeline and determined that the development of Fexuprazan no longer aligns with its strategic business plan. Dae

LAKE ZURICH, Ill., June 5, 2023 /PRNewswire/ -- RLS (USA), Inc. (Radioisotope Life Sciences), the third-largest nuclear medicine pharmacy network in the US, has been awarded a national group purchasing agreement for the distribution of Radiopharmaceutical Products with Premier, Inc, a leading healthcare improvement company headquartered in Charlotte, North Carolina. Effective July 1, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and